Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)
Blood tests can now identify which lung cancer patients benefit most from a specific targeted drug, guiding personalized treatment decisions.
This addendum to the RELAY Phase 3 RCT applies circulating cell-free DNA profiling to EGFR-mutated metastatic NSCLC patients to identify which mutation profiles benefit most from ramucirumab. The findings demonstrate clinical utility of liquid biopsy in guiding targeted therapy decisions in a validated Phase 3 setting.
What the study was
- Study design
- Phase 3 RCT addendum / biomarker sub-study
- Population
- EGFR-mutated metastatic NSCLC patients (RELAY Phase 3 trial, Japan cohort)
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- JTO Clinical and Research Reports
Why it surfaced
Phase 3 RCT addendum with cfDNA profiling enabling mutation-specific treatment selection in EGFR NSCLC; directly addresses liquid biopsy translation to clinical practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.